Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3077314 | 0.82 | ALDH1A1 (0.35) | TSHRALDH1A1 | |
| SCHEMBL17953040 | 0.82 | ALDH1A1 (0.35) | TSHRALDH1A1 | |
| SCHEMBL3246786 | 0.82 | TSHR (0.39) | TSHRALDH1A1 | |
| SCHEMBL6151164 | 0.82 | CA2 (0.32) | TSHRALDH1A1 | |
| SCHEMBL271740 | 0.79 | — | — | |
| SCHEMBL959151 | 0.79 | — | — | |
| SCHEMBL6986580 | 0.79 | — | — | |
| SCHEMBL116714 | 0.79 | — | — | |
| SCHEMBL3917530 | 0.77 | FKBP1A (0.33) | TSHR | |
| SCHEMBL3832588 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9557297-B2 | Alpha- and chi-diketone reactants for charge transfer reactions in mass spectrometers | BRUKER DALTONIK GMBH (DE) | 2017-01-31 | — | — | US | claimed |
| US-20130115711-A1 | REACTANTS FOR CHARGE TRANSFER REACTIONS IN MASS SPECTROMETERS | BRUKER DALTONIK GMBH (DE) | 2013-05-09 | — | — | US | claimed |
| EP-0233510-B1 | PROCESS FOR THE PRODUCTION OF DI-TERT.-BUTYL-ETHYLENE DIAMINE | BASF Aktiengesellschaft (DE) | 1990-04-11 | — | — | EP | claimed |
| CN-119126287-A | Polarizing plate and optical display device | 三星SDI株式会社 | 2024-12-13 | — | — | CN | disclosed |
| US-20240411077-A1 | POLARIZING PLATE AND OPTICAL DISPLAY DEVICE | Wuxi Hengxin Optoelectronic Materials Co., Ltd. (CN) | 2024-12-12 | — | — | US | disclosed |
| US-20230190782-A1 | NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230056135-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | EMORY UNIVERSITY (US) | 2023-02-23 | — | — | US | disclosed |
| CN-109641927-B | Method for producing thin inorganic films | 巴斯夫欧洲公司 | 2023-01-10 | — | — | CN | disclosed |
| WO-2022070552-A1 | ACTIVE-ENERGY-RAY-CURABLE COMPOSITION AND METHOD FOR PRODUCING PRINTED MATTER USING SAME, AND METHOD FOR IMPROVING ADHESION OF ACTIVE-ENERGY-RAY-CURABLE VARNISH COMPOSITION TO PRINTED MATTER SURFACE | サカタインクス株式会社 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022024512-A1 | ACTIVE ENERGY RAY-CURABLE INK COMPOSITION FOR OFFSET PRINTING | サカタインクス株式会社 | 2022-02-03 | — | — | WO | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| US-6603007-B1 | Intermediates in the fields of pharmaceuticals, agrichemicals, ligands, silver halide photosensitive materials, liquid crystals, surfactants, electrophotography and organic electroluminescence | SANKIO CHEMICAL CO., LTD. (JP) | 2003-08-05 | — | — | US | disclosed |
| CN-1390202-A | Novel bipyridyl derivatives | SANKIO CHEMICAL CO LTD (JP) | 2003-01-08 | — | — | CN | disclosed |
| EP-1231207-A1 | NOVEL BIPYRIDYL DERIVATIVES | Sankio Chemical Co., Ltd. (JP) | 2002-08-14 | — | — | EP | disclosed |
| US-20020027415-A1 | Organic electroluminescent device containing dithiafulvene derivative | CHISSO CORPORATION (JP) | 2002-03-07 | — | — | US | disclosed |
| US-5068477-A | Impregnation with reducing agent, decomposition with heat and drying | EUROPEENNE DE RETRAITEMENT DE CATALYSEURS EURECAT (FR) | 1991-11-26 | — | — | US | disclosed |
| US-5059731-A | Selectively hydrogenating acetylenic and diolefinic hydrocarbons | EUROPEANE DE RETRAITEMENT DE CATALYSEURS EURECAT (FR) | 1991-10-22 | — | — | US | disclosed |
| US-5032565-A | Using aldehyde, ketone, alcohol, ether or acid | EUROPEENNE RETRAITEMENT DE CATALYSEURS EURECAT (FR) | 1991-07-16 | — | — | US | disclosed |
| CN-1031247-A | A kind of catalyst for refining method of reducing before use | EURECAT EUROP RETRAIT CATALYS (FR) | 1989-02-22 | — | — | CN | disclosed |
| US-4530917-A | Using a polysulfide sulfuration agent | EURECAT - SOCIETE EUROPEENNE DE RETRAITEMENT DE CATALYSEURS (FR) | 1985-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | TSHR 3853/4885ALDH1A1 4678/4885LMNA 4788/4885 |
| US-20230190782-A1 | NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF | TYMP, NUDT1, PNP | TSHR 4766/4885ALDH1A1 1755/4885LMNA 463/4885 |
| US-20230056135-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | HAVCR2, HMBS, HDGF | TSHR 4386/4885ALDH1A1 2529/4885LMNA 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.